Mentari Therapeutics

Mentari Therapeutics is a private biotechnology company developing antibody-based therapies for migraine prevention. The company is focused on patients with chronic and episodic migraine, particularly those who do not respond adequately to existing calcitonin gene-related peptide-targeted therapies. Its lead pipeline includes MT-001, an anti-PACAP monoclonal antibody, and MT-002, an anti-CGRP + anti-PACAP bispecific antibody, both discovered through Paragon Therapeutics. As of May 19, 2026, Mentari had announced a reverse merger with InMed Pharmaceuticals alongside a $290 million private financing intended to fund operations through key clinical milestones into 2028. The combined company is expected to operate under the Mentari Therapeutics name following closing.